Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS

Author(s): Wang Aitong , Zhang Leisheng and Yu Hao*

Volume 17, Issue 1, 2022

Published on: 12 July, 2021

Page: [2 - 12] Pages: 11

DOI: 10.2174/1574888X16666210712212421

Price: $65

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a widespread pandemic globally and seriously threatened public health. Patients with COVID-19 infection, and in particular, those with severe pneumonia-associated acute respiratory distress syndrome (ARDS) manifested rapid disease progression and the resultant high mortality and morbidity. Advances in fundamental and clinical studies have suggested the feasibility of mesenchymal stem/stromal cell (MSC)-based therapy as an inspiring alternative for ARDS administration. However, the systematic characteristics of the MSC-based cytotherapy and underlying mechanism for COVID-19 associated ARDS by bibliometric analyses are still unknowable. Herein, we took advantage of visual analyses to reveal the overview of ARDS-associated updates, core authors and focused issues, as well as to summarize the comprehensive knowledge of the keywords, authors, institutions with the aid of indicated software. Meanwhile, we have provided a brief overview on the molecular mechanisms and discussed the safety and efficacy of MSC-based therapy for ARDS on the basis of clinical trials.

Keywords: Mesenchymal stem/stromal cells (MSCs), acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), bibliometric analyses, mechanisms, clinical trials.

« Previous Next »
Graphical Abstract

[1]
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China-key questions for impact assessment. N Engl J Med 2020; 382(8): 692-4.
[http://dx.doi.org/10.1056/NEJMp2000929] [PMID: 31978293]
[2]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[3]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[4]
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470-3.
[http://dx.doi.org/10.1016/S0140-6736(20)30185-9] [PMID: 31986257]
[5]
Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A 2018; 93(1): 19-31.
[http://dx.doi.org/10.1002/cyto.a.23242] [PMID: 29072818]
[6]
Feng Y, Wang AT, Jia HH, Zhao M, Yu H. A brief analysis of mesenchymal stem cells as biological drugs for the treatment of acute-on-chronic liver failure (ACLF): Safety and potency. Curr Stem Cell Res Ther 2020; 15(3): 202-10.
[http://dx.doi.org/10.2174/1574888X15666200101124317] [PMID: 31893994]
[7]
Bhansali S, Dutta P, Kumar V, et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: A randomized, placebo- controlled comparative study. Stem Cells Dev 2017; 26(7): 471-81.
[http://dx.doi.org/10.1089/scd.2016.0275] [PMID: 28006991]
[8]
Wang AT, Feng Y, Jia HH, Zhao M, Yu H. Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review. World J Stem Cells 2019; 11(4): 222-35.
[http://dx.doi.org/10.4252/wjsc.v11.i4.222] [PMID: 31110603]
[9]
Makhlough A, Shekarchian S, Moghadasali R, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up. Cytotherapy 2018; 20(5): 660-9.
[http://dx.doi.org/10.1016/j.jcyt.2018.02.368] [PMID: 29580865]
[10]
Bartolucci J, Verdugo FJ, González PL, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (rimecard trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res 2017; 121(10): 1192-204.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.310712] [PMID: 28974553]
[11]
Gupta PK, Chullikana A, Parakh R, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 2013; 11: 143.
[http://dx.doi.org/10.1186/1479-5876-11-143] [PMID: 23758736]
[12]
Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med 2020; 9(9): 1007-22.
[http://dx.doi.org/10.1002/sctm.20-0146] [PMID: 32472653]
[13]
Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep 2020; 26: e00467.
[http://dx.doi.org/10.1016/j.btre.2020.e00467] [PMID: 32420049]
[14]
Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: From basic to clinics. Protein Cell 2020; 11(10): 707-22.
[http://dx.doi.org/10.1007/s13238-020-00738-2] [PMID: 32519302]
[15]
Teoh N, Farrell G. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome- time is of the essence. J Clin Transl Res 2020; 5(5): 227-9.
[PMID: 32617428]
[16]
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet 2020; 395(10226): 809-15.
[http://dx.doi.org/10.1016/S0140-6736(20)30360-3] [PMID: 32151335]
[17]
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1-9.
[PMID: 32105090]
[18]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[19]
Esquivel D, Mishra R, Srivastava A. Stem cell therapy offers a possible safe and promising alternative approach for treating vitiligo: A review. Curr Pharm Des 2020; 26(37): 4815-21.
[http://dx.doi.org/10.2174/1381612826666200730221446] [PMID: 32744962]
[20]
Shao M, Xu Q, Wu Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther 2020; 11(1): 37.
[http://dx.doi.org/10.1186/s13287-020-1550-0] [PMID: 31973730]
[21]
Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 2018; 14(8): 493-507.
[http://dx.doi.org/10.1038/s41581-018-0023-5] [PMID: 29895977]
[22]
Pooja Y, Ravina V, Afsareen B, Rashmi B. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci 2020; 263: 118588.
[23]
Johnson CL, Soeder Y, Dahlke MH. Concise review: Mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Transl Med 2017; 6(4): 1141-51.
[http://dx.doi.org/10.1002/sctm.16-0415] [PMID: 28186706]
[24]
Ðokić JM, Tomić SZ, Čolić MJ. Cross-talk between mesenchymal stem/stromal cells and dendritic cells. Curr Stem Cell Res Ther 2016; 11(1): 51-65.
[http://dx.doi.org/10.2174/1574888X10666150904114035] [PMID: 26337378]
[25]
Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ 2018; 25(7): 1209-23.
[http://dx.doi.org/10.1038/s41418-017-0006-2] [PMID: 29238069]
[26]
Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: Mode of action and pathways. Ann N Y Acad Sci 2015; 1351: 114-26.
[http://dx.doi.org/10.1111/nyas.12815] [PMID: 26152292]
[27]
Leng Z, Zhu R, Hou W, et al. Transplantation of ace2- mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Dis 2020; 11(2): 216-28.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[28]
Ito JT, Lourenço JD, Righetti RF, Tibério IFLC, Prado CM, Lopes FDTQS. Extracellular matrix component remodeling in respiratory diseases: What has been found in clinical and experimental studies? Cells 2019; 8(4): 342.
[http://dx.doi.org/10.3390/cells8040342] [PMID: 30979017]
[29]
Kuhn H, Zobel C, Vollert G, et al. High amplitude stretching of ATII cells and fibroblasts results in profibrotic effects. Exp Lung Res 2019; 45(7): 167-74.
[http://dx.doi.org/10.1080/01902148.2019.1636424] [PMID: 31290711]
[30]
Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33(2): 145-52.
[http://dx.doi.org/10.1165/rcmb.2004-0330OC] [PMID: 15891110]
[31]
Jiang X, Jiang X, Qu C, et al. Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats. Cytotherapy 2015; 17(5): 560-70.
[http://dx.doi.org/10.1016/j.jcyt.2015.02.011] [PMID: 25791071]
[32]
Mahmoudi T, Abdolmohammadi K, Bashiri H, et al. Hydrogen peroxide preconditioning promotes protective effects of umbilical cord vein mesenchymal stem cells in experimental pulmonary fibrosis. Adv Pharm Bull 2020; 10(1): 72-80.
[http://dx.doi.org/10.15171/apb.2020.009] [PMID: 32002364]
[33]
Yi Y, Shu H, Xu X, et al. The vascular endothelial growth factors- expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediat Inflamm 2016; 2016: 2347938.
[34]
Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009; 106(38): 16357-62.
[http://dx.doi.org/10.1073/pnas.0907996106] [PMID: 19721001]
[35]
Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res 2014; 15(1): 39.
[http://dx.doi.org/10.1186/1465-9921-15-39] [PMID: 24708472]
[36]
Chang Y, Park SH, Huh JW, Lim CM, Koh Y, Hong SB. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome. J Korean Med Sci 2014; 29(3): 438-40.
[http://dx.doi.org/10.3346/jkms.2014.29.3.438] [PMID: 24616596]
[37]
Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015; 3(1): 24-32.
[http://dx.doi.org/10.1016/S2213-2600(14)70291-7] [PMID: 25529339]
[38]
Simonson OE, Mougiakakos D, Heldring N, et al. in vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med 2015; 4(10): 1199-213.
[http://dx.doi.org/10.5966/sctm.2015-0021] [PMID: 26285659]
[39]
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial. Lancet Respir Med 2019; 7(2): 154-62.
[http://dx.doi.org/10.1016/S2213-2600(18)30418-1] [PMID: 30455077]
[40]
Yip HK, Fang WF, Li YC, et al. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med 2020; 48(5): e391-9.
[http://dx.doi.org/10.1097/CCM.0000000000004285] [PMID: 32187077]
[41]
Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering (Beijing) 2020; 6(10): 1153-61.
[42]
Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 2020; 11(1): 361.
[http://dx.doi.org/10.1186/s13287-020-01875-5] [PMID: 32811531]
[43]
Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med 2020; 14(5): 664-73.
[http://dx.doi.org/10.1007/s11684-020-0810-9] [PMID: 32761491]
[44]
Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 2020; 11(1): 207.
[http://dx.doi.org/10.1186/s13287-020-01725-4] [PMID: 32460839]
[45]
Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine 2020; 99(31): e21429.
[http://dx.doi.org/10.1097/MD.0000000000021429] [PMID: 32756149]
[46]
Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: A phase 1 clinical trial. Signal Transduct Tar 2020; 5(0): 11.
[47]
Chen H, Zhang L, He Z, Wang D, Liu L, Zhang W. Systemic administration of human umbilical cord-derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID-19 with multiple comorbidities: A case report. World Acad Sci J 2020; 2: 29.

Rights & Permissions Print Cite
Article Metrics
71
4
© 2024 Bentham Science Publishers | Privacy Policy